La vendita allo scoperto per Cumberland dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Cumberland. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Cumberland (NASDAQ:CPIX) Azioni, Report sulle vendite allo scoperto

Cumberland

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland Pharmaceuticals Inc

Biotech

News

General

CPIX

Cumberland Pharmaceuticals Receives FDA Orphan Drug, Rare Pediatric Disease Designations For New Treatment Of Duchenne Muscular Dystrophy

–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real World Study Compared Over 150,000 Adult &amp; Pediatric Patients – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor Associated with Fewer Adverse Drug Reactions – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor also Improved Healthcare Utilization –
NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations. The study, published in Frontiers of Pain Research, provides compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions (ADRs) and improved healthcare utilizations when compared to ketorolac.
This extensive, retrospective, payer database analysis evaluated the records of over 17 million patients who had received either ketorolac or Caldolor. Ultimately, 31,046 Caldolor and 124,184 ketorolac adult patients were selected and compared for ADRs and subsequent healthcare resource utilization, which includes inpatient, outpatient and emergency department visits as well as all procedures and prescriptions during the follow up time of 29 days. An additional 5,579 pediatric patients were identified in each arm and compared in a separate claims analysis.
Key findings reveal that, in adults, Caldolor was associated with a 45% reduction in renal dysfunction (p&lt;0.001) and a 78% decrease in hematuria rates (p&lt;0.001) when compared to ketorolac. Notably, patients also experienced fewer gastrointestinal complications as well as reduced headaches, nausea and abdominal pain. Among pediatric patients, the results showed Caldolor was associated with a 51-65% lower rate of ADRs, including headache and nausea, with 95% confidence intervals supporting clinical significance.
Caldolor also demonstrated a positive impact on healthcare resource utilization (HCRU) when compared to ketorolac, with decreased emergency room and outpatient visits, as well as a shortened hospital length of stay for both adults and children.

Cumberland Pharmaceuticals Announces The Publication Of New Real-World Outcomes Research Demonstrating The Safety And Healthcare Resource Advantages Of Its Caldolor (Ibuprofen) Injection Over Ketorolac In Both Adult And Pediatric Populations

Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) reported quarterly earnings of $0.01 per share. This is a 93.75 percent decrease over earnings of $0.16 per share from the same period last year. The company reported $9.85 million in sales this quarter. This is a 9.55 percent decrease over sales of $10.89 million the same period last year.

Earnings

Cumberland Q2 Adj $0.01 Down From $0.16 YoY, Sales $9.85M Down From $10.89M YoY

Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) reported quarterly losses of $(0.05) per share. This is a 145.45 percent decrease over earnings of $0.11 per share from the same period last year. The company reported $8.50 million in sales this quarter. This is a 7.88 percent decrease over sales of $9.22 million the same period last year.

Cumberland Q1 Adj $(0.05) Down From $0.11 YoY, Sales $8.50M Down From $9.22M YoY

Cumberland Pharmaceuticals Q4 2023 Adj. EPS $(0.11) Down From $(0.05) YoY; Revenue $9.353M Up From $9.123M Est.

<h3>Companies Reporting Before The Bell</h3>
&bull; NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion.
&bull; Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is estimated to report quarterly earnings at $2.22 per share on revenue of $29.33 billion.
&bull; 2seventy bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) is expected to report quarterly loss at $0.99 per share on revenue of $14.71 million.
&bull; CLPS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPS#NASDAQ">CLPS</a>) is expected to report earnings for its first quarter.
&bull; Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) is projected to report quarterly loss at $0.50 per share on revenue of $350 thousand.
&bull; Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $183.67 million.
&bull; Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) is projected to report quarterly loss at $1.39 per share on revenue of $2.55 million.
&bull; Consolidated Comms Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSL#NASDAQ">CNSL</a>) is likely to report quarterly loss at $0.36 per share on revenue of $276.94 million.
&bull; CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) is likely to report quarterly earnings at $0.24 per share on revenue of $146.61 million.
&bull; 908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) is expected to report quarterly loss at $0.26 per share on revenue of $14.16 million.
&bull; Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) is projected to report quarterly loss at $0.26 per share on revenue of $19.85 million.
&bull; Broadwind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWEN#NASDAQ">BWEN</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $50.15 million.
&bull; Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) is projected to report quarterly loss at $0.03 per share on revenue of $541.17 million.
&bull; Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $84.02 million.
&bull; Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $9.00 million.
&bull; L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $129.35 million.
&bull; Rand Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAND#NASDAQ">RAND</a>) is expected to report earnings for its fourth quarter.
&bull; Dave (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAVE#NASDAQ">DAVE</a>) is likely to report earnings for its fourth quarter.
&bull; Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) is projected to report quarterly loss at $0.26 per share on revenue of $17.33 million.
&bull; First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $237.53 million.
&bull; Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) is likely to report quarterly earnings at $0.22 per share on revenue of $20.00 million.
&bull; SmartRent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) is likely to report quarterly loss at $0.01 per share on revenue of $59.49 million.
&bull; Ferguson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) is estimated to report quarterly earnings at $1.85 per share on revenue of $6.77 billion.
&bull; Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $41.78 million.
&bull; Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) is likely to report quarterly loss at $0.10 per share on revenue of $41.65 million.
&bull; V2X (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVX#NYSE">VVX</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $1.01 billion.
&bull; Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) is likely to report earnings for its fourth quarter.
&bull; Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) is expected to report quarterly earnings at $0.26 per share on revenue of $196.19 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is estimated to report quarterly earnings at $0.80 per share on revenue of $197.70 million.
&bull; Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is estimated to report quarterly earnings at $0.88 per share on revenue of $4.39 billion.
&bull; BlackRock Cap Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKCC#NASDAQ">BKCC</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $20.32 million.
&bull; Presto Automation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) is likely to report earnings for its fourth quarter.
&bull; Kingsway Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFS#NYSE">KFS</a>) is likely to report earnings for its fourth quarter.
&bull; Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) is expected to report quarterly loss at $0.19 per share on revenue of $293.53 million.
&bull; Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) is likely to report earnings for its fourth quarter.
&bull; TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) is likely to report quarterly loss at $0.08 per share on revenue of $1.00 million.
&bull; Entravision Comms (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVC#NYSE">EVC</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $308.47 million.
&bull; Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) is projected to report quarterly loss at $0.87 per share on revenue of $10.58 million.
&bull; Inspirato (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPO#NASDAQ">ISPO</a>) is likely to report quarterly loss at $3.66 per share on revenue of $73.50 million.
&bull; Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) is expected to report quarterly loss at $0.62 per share on revenue of $8.01 million.
&bull; Allient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNT#NASDAQ">ALNT</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $132.56 million.
&bull; Bristow Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTOL#NYSE">VTOL</a>) is projected to report quarterly earnings at $0.54 per share on revenue of $329.20 million.
&bull; Greenlight Capital Re (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLRE#NASDAQ">GLRE</a>) is estimated to report earnings for its fourth quarter.
&bull; Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $34.10 million.
&bull; Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) is projected to report quarterly loss at $1.07 per share on revenue of $1.06 million.
&bull; Socket Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCKT#NASDAQ">SCKT</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $4.91 million.
&bull; Nyxoah (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYXH#NASDAQ">NYXH</a>) is expected to report quarterly loss at $0.40 per share on revenue of $1.95 million.
&bull; Park-Ohio Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PKOH#NASDAQ">PKOH</a>) is likely to report quarterly earnings at $0.55 per share on revenue of $386.45 million.
&bull; W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $138.42 million.
&bull; Cadre Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDRE#NYSE">CDRE</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $121.79 million.
&bull; Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $14.50 million.
&bull; Agiliti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGTI#NYSE">AGTI</a>) is projected to report quarterly earnings at $0.11 per share on revenue of $291.41 million.
&bull; Nuvei (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVEI#NASDAQ">NVEI</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $319.51 million.
&bull; Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) is estimated to report quarterly earnings at $0.84 per share on revenue of $283.00 million.
&bull; Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $152.30 million.
&bull; Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) is likely to report quarterly loss at $0.08 per share on revenue of $11.63 million.
&bull; Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) is expected to report earnings for its fourth quarter.
&bull; MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $74.86 million.
&bull; Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) is likely to report earnings for its fourth quarter.
&bull; Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) is expected to report quarterly loss at $0.02 per share on revenue of $49.27 million.
&bull; American Public Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $150.47 million.
&bull; Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $249.68 million.
&bull; Crexendo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $13.80 million.
&bull; Aeva Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NYSE">AEVA</a>) is likely to report quarterly loss at $0.15 per share on revenue of $1.57 million.
&bull; LSB Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXU#NYSE">LXU</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $127.21 million.
&bull; PlayAGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGS#NYSE">AGS</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $92.57 million.
&bull; Full House Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLL#NASDAQ">FLL</a>) is likely to report quarterly loss at $0.14 per share on revenue of $63.13 million.
&bull; CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is expected to report quarterly earnings at $0.82 per share on revenue of $839.04 million.
&bull; HashiCorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCP#NASDAQ">HCP</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $149.29 million.
&bull; Banco BBVA Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAR#NYSE">BBAR</a>) is estimated to report earnings for its fourth quarter.
&bull; NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) is expected to report quarterly loss at $0.31 per share on revenue of $17.46 million.
&bull; Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) is projected to report earnings for its fourth quarter.
&bull; Ooma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $61.46 million.
&bull; ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) is likely to report quarterly loss at $0.13 per share on revenue of $119.59 million.
&bull; ODDITY Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) is expected to report earnings for its fourth quarter.
&bull; NewtekOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWT#NASDAQ">NEWT</a>) is projected to report quarterly earnings at $0.58 per share on revenue of $63.35 million.
&bull; Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) is expected to report quarterly earnings at $0.38 per share on revenue of $262.95 million.
&bull; Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) is projected to report earnings for its fourth quarter.
&bull; Alexandria Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARE#NYSE">ARE</a>) is likely to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AEVA

AGTI

ALNT

AOMR

APEI

AQST

AXGN

BASE

BBAR

BKCC

BNGO

BWEN

CDRE

CECO

CERS

CGEN

CHPT

CIFR

CLPS

CNSL

CRCT

CRWD

CXDO

DAVE

FERG

FSTR

FWRG

GBTG

GLRE

ISPO

MASS

MCRB

MLNK

MRNS

NEWT

NPCE

NUWE

NVEI

NYXH

OFIX

OOMA

PKOH

PRST

PSTV

RAND

RIGL

ROST

RSKD

SCKT

SEAT

SMLR

SMRT

SOPH

STIM

TCON

TSVT

VTOL

WEYS

Earnings Scheduled For March 5, 2024

Cumberland Pharmaceuticals Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) announced today a new publication in Antimicrobial Agents and Chemotherapy1 detailing the results of the first clinical study investigating the safety and pharmacokinetics of Vibativ&#xAE; (telavancin) injection in children 2 to 17 years of age. Vibativ&nbsp;is an intravenous antibiotic approved by the FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) as well as complicated skin and skin structure infections (cSSSIs) caused by certain gram-positive bacteria in adults2. This is the first reported study evaluating Vibativ in pediatric patients.
&nbsp;
"Methicillin-resistant Staphylococcus aureus (MRSA) continues to be a problem for children. New, effective and safe therapy, particularly once-daily therapy, will be welcomed by those who care for children with serious MRSA infections requiring intravenous therapy," said first author Dr. John Bradley, Distinguished Professor of Pediatrics, University of California San Diego School of Medicine and Medical Director of Infectious Disease at Rady Children's Hospital of San Diego.&nbsp;
This publication describes results of an open-label study aimed at characterizing a single 10 mg/kg dose of Vibativ in children 2 to 17 years of age who required systemic antibiotics for the treatment of a known or suspected bacterial infection. Of the 22 patients treated in the study, 14 were 12 to 17 years of age, 7 were 6 to 11 years of age and one was 2 years of age. The study found a single 10 mg/kg dose of Vibativ was safe with no serious adverse events or renal concerns. Drug exposure to Vibativ was lower in children compared with observations in adult patients3.
"Antimicrobial resistance poses a significant challenge in the treatment of bacterial infections, necessitating the development of new antibiotic therapies. The results of this study suggest that a single dose of Vibativ is safe in children and they experience reduced exposure to Vibativ, compared with the same body weight-based dosing in adults," said corresponding author Dr. Antonio Arrieta, Professor of Pediatrics, University of California Irvine and Medical Director of Pediatric Infectious Disease, Children's Hospital of Orange County.
For full prescribing and important safety information, please see the brand's website at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3992822-1&amp;h=556605691&amp;u=http%3A%2F%2Fwww.vibativ.com%2F&amp;a=www.vibativ.com">www.vibativ.com</a>.
<ol>
<li>Bradley&nbsp;JS, Goldman JL, James, LP, Kaelin B, Gibson BHY, Arrieta A. Pharmacokinetics and Safety of a Single Dose of Telavancin in Pediatric Subjects Aged 2 to 17 Years of Age. Antimicrob Agents Chemother. October 10, 2023.</li>
<li>Vibativ&#xAE; (telavancin) [Package Insert]. Cumberland Pharmaceuticals Inc. Nashville, TN; 2020.</li>
<li>Worboys PD, Wong SL, Barriere SL. Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Eur J Clin Pharmacol. 2015 Jun 1;71(6):707–14.</li>
</ol>
About Vibativ&#xAE; (telavancin) for Injection
Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia and complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant. Intravenous unfractionated heparin sodium is contraindicated with Vibativ administration due to artificially prolonged activated partial thromboplastin time (aPTT) test results for up to 18 hours after Vibativ administration. Vibativ is contraindicated in patients with a known hypersensitivity to telavancin. For more information please visit <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3992822-1&amp;h=556605691&amp;u=http%3A%2F%2Fwww.vibativ.com%2F&amp;a=www.vibativ.com">www.vibativ.com</a>.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. The company develops, acquires, and commercializes brands for the hospital acute care, gastroenterology and rheumatology market segments. The company's portfolio of FDA-approved brands includes:
<ul>
<li>Acetadote&#xAE; (acetylcysteine) injection, for the treatment of acetaminophen poisoning;</li>
<li>Caldolor&#xAE;&nbsp;(ibuprofen) injection, for the treatment of pain and fever;</li>
<li>Kristalose&#xAE; (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;</li>
<li>Omeclamox&#xAE;-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease;</li>
<li>Sancuso&#xAE;&nbsp;(granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;</li>
<li>Vaprisol&#xAE;&nbsp;(conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and</li>
<li>Vibativ&#xAE;&nbsp;(telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.</li>
</ul>
The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidates in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy ("DMD") and Systemic Sclerosis ("SSc").
For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the company's website <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=3992822-1&amp;h=1267620474&amp;u=http%3A%2F%2Fwww.cumberlandpharma.com%2F&amp;a=www.cumberlandpharma.com">www.cumberlandpharma.com</a>.
Forward-looking Statements:

Cumberland Pharmaceuticals Announces New Vibatv Pediatric Publication Highlights Its Safety In Patients 2 To 17 Years Of Age

Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) reported quarterly earnings of $0.16 per share. This is a 1700 percent increase over losses of $(0.01) per share from the same period last year. The company reported $10.89 million in sales this quarter. This is a 5.73 percent increase over sales of $10.30 million the same period last year.

Cumberland Q2 Adj EPS $0.16 Up From $(0.01) YoY, Sales $10.89M Up From $10.30M YoY

Cumberland Pharmaceuticals Announces Publication Of Results From Clinical Study Investigating The Safety And Pharmacokinetics Of Caldolor In Newborn Pediatric Patients

Guidance

Cumberland Pharmaceuticals Said On June 2 FDA Informed Co That It Had Granted A Barrier-to-Innovation Waiver Associated With Reditrex Product Line Which Will Result In Refund Of ~$1.2M Co Paid For Prescription Drug Program Fees For Reditrex Product Line

<h3>Gainers</h3>
<ul>
<li>CohBar, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cwbr#NASDAQ">CWBR</a>) shares jumped 161% to $4.05 after the company and Morphogenesis announced they have entered into a definitive agreement for an all-stock transaction forming a company combining expertise and resources to advance a late-stage oncology pipeline.</li>
<li>HeartCore Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/htcr#NASDAQ">HTCR</a>) gained 76.6% to $2.26 following better-than-expected first-quarter results.</li>
<li>Ocean Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocea#NASDAQ">OCEA</a>) shares climbed 63% to $8.57 after the company announced a patent award for novel cancer immunotherapy treatment, granted for prostate cancer, colon cancer, ovarian cancer, kidney cancer, breast cancer, glioblastoma, melanoma and lung cancer.</li>
<li>Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/shph#NASDAQ">SHPH</a>) surged 44% to $1.50 after it was granted U.S. patent #11654157: Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation.</li>
<li>Unique Fabricating, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ufab#NYSE">UFAB</a>) climbed 32.8% to $0.2599 after the company announced an accommodation agreement and new forbearance agreement to support a restructuring or sale.</li>
<li>Icosavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/icvx#NASDAQ">ICVX</a>) gained 29.7% to $10.21 after the company announced topline interim Phase 1 results for its bivalent VLP vaccine candidate IVX-A12 against RSV and hMPV in older adults.</li>
<li>mCloud Technologies Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mcld#NASDAQ">MCLD</a>) jumped 27% to $0.4567 after the company announced it has formed a special committee for the purpose of exploring strategic alternatives.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxrx#NASDAQ">RXRX</a>) gained 22.6% to $9.96.</li>
<li>IMAC Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/back#NASDAQ">BACK</a>) climbed 21.9% to $0.1702. Theralink signed definitive merger agreement to be acquired by IMAC Holdings.</li>
<li>TuSimple Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsp#NASDAQ">TSP</a>) climbed 21.2% to $2.01.</li>
<li>Lexaria Bioscience Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lexx#NASDAQ">LEXX</a>) climbed 20.4% to $0.83. Lexaria Bioscience recently announced it completed its HOR-A22-1 study that showed significant enhancement in the oral delivery of the estrogen hormone estradiol.</li>
<li>PacWest Bancorp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pacw#NASDAQ">PACW</a>) shares gained 20% to $8.23. PacWest Bancorp shares jumped around 20% on Monday after the company announced it entered into a loan purchase and sale agreement with a subsidiary of Kennedy-Wilson Holdings to sell a portfolio of 74 real estate construction loans. DA Davidson maintained PacWest Banc with a Neutral and raised the price target from $3 to $8.</li>
<li>Lifecore Biomedical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lfcr#NASDAQ">LFCR</a>) shares gained 18% to $6.32 after the company announced it entered into $150 million in new financing, repaid its outstanding term loans and signed a new supply agreement to expact its HA fermentation capacity with Alcon.</li>
<li>Quanterix Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qtrx#NASDAQ">QTRX</a>) gained 17.5% to $22.59. Goldman Sachs upgraded Quanterix from Neutral to Buy and raised the price target from $13 to $27.</li>
<li>Applied UV, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/auvi#NASDAQ">AUVI</a>) shares climbed 15.6% to $0.5512 after posting better-than-expected quarterly sales.</li>
<li>Angion Biomedica Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/angn#NASDAQ">ANGN</a>) gained 15.1% to $0.9159.</li>
<li>SeqLL Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sql#NASDAQ">SQL</a>) shares surged 15% to $0.46 after gaining over 19% on Monday. SeqLL recently posted a wider first-quarter loss.</li>
<li>Navigator Holdings Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvgs#NYSE">NVGS</a>) rose 14.2% to $15.00 following strong quarterly sales.</li>
<li>Myriad Genetics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mygn#NASDAQ">MYGN</a>) gained 12.9% to $22.67. Goldman Sachs upgraded Myriad Genetics from Sell to Buy and raised the price target from $18 to $25.</li>
<li>Sarcos Technology and Robotics Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/strc#NASDAQ">STRC</a>) surged 11.7% to $0.3857.</li>
<li>Wallbox N.V. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wbx#NYSE">WBX</a>) surged 11.2% to $3.9583.</li>
<li>Terns Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tern#NASDAQ">TERN</a>) jumped 11.2% to $12.55.</li>
<li>AbCellera Biologics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abcl#NASDAQ">ABCL</a>) gained 11% to $7.34.</li>
<li>Movella Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mvla#NASDAQ">MVLA</a>) rose 9.9% to $2.11 after jumping around 18% on Monday.</li>
<li>CureVac N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cvac#NASDAQ">CVAC</a>) surged 9.5% to $10.59.</li>
<li>Yelp Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/yelp#NYSE">YELP</a>) gained 9.2% to $35.51. Activist investor TCS Capital Management has built a stake in Yelp and urged the service-recommendation site to explore strategic alternatives, including a sale, the Wall Street Journal reported.</li>
<li>Cumberland Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cpix#NASDAQ">CPIX</a>) shares rose 5.8% to $1.84. The FDA recently approved expanded labeling for Cumberland Pharmaceuticals&rsquo; Caldolor, an intravenously delivered formulation of ibuprofen, to now include use in infants.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Netcapital Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncpl#NASDAQ">NCPL</a>) shares fell 32.8% to $1.62 after the company reported a registered direct offering of 1.1 million shares at $1.55 per share.</li>
<li>T2 Biosystems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttoo#NASDAQ">TTOO</a>) dropped 29% to $0.2001 after the company posted downbeat quarterly results and announced exploration of strategic alternatives and implementation of a restructuring program, including 30% incremental reduction of workforce completed this past week.</li>
<li>Kaspien Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kspn#NASDAQ">KSPN</a>) fell 27.6% to $0.4427. Kaspien Holdings reported voluntary delisting from the Nasdaq Capital Market effective on or about June 12.</li>
<li>Evolve Transition Infrastructure LP (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/snmp#NYSE">SNMP</a>) dipped 26.6% to $0.0901 after the company announced a 1-for-30 reverse split.</li>
<li>Microvast Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mvst#NASDAQ">MVST</a>) fell 22.3% to $1.71 after the US Energy Department reportedly cancelled contract negotiations for a $200 million award for the company.</li>
<li>Microbot Medical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mbot#NASDAQ">MBOT</a>) fell 22.1% to $2.4850. Microbot Medical announced a $1.44 million registered direct offering of 655,569 shares of common stock at a price of $2.20 per share priced at the market under Nasdaq rules.</li>
<li>NantHealth, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nh#NASDAQ">NH</a>) fell 20.6% to $2.04.</li>
<li>Oncorus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oncr#NASDAQ">ONCR</a>) dropped 20% to $0.2480 after the company reported Q1 financial results.</li>
<li>Meihua International Medical Technologies Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mhua#NASDAQ">MHUA</a>) dropped 20% to $2.96.</li>
<li>D-Wave Quantum Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/qbts#NYSE">QBTS</a>) fell 16.7% to $0.8501 after surging 110% on Monday.</li>
<li>Tenon Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tnon#NASDAQ">TNON</a>) declined 16.1% to $1.36. Tenon Medical recently posted downbeat quarterly results.</li>
<li>NexImmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexi#NASDAQ">NEXI</a>) dropped 15.2% to $0.4018.</li>
<li>Achieve Life Sciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/achv#NASDAQ">ACHV</a>) declined 14.7% to $6.95 as the company reported topline results from Phase 3 ORCA-3 trial of cytisinicline.</li>
<li>Integra LifeSciences Holdings Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iart#NASDAQ">IART</a>) fell 13.5% to $43.87 after the company announced it initiated a voluntary global recall of all products manufactured in its Boston facility distributed between March 1, 2018 and May 22, 2023.</li>
<li>Voyager Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vygr#NASDAQ">VYGR</a>) fell 10.6% to $12.37.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kc#NASDAQ">KC</a>) dropped 10% to $4.2750 following weak quarterly results.</li>
<li>Biocept, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bioc#NASDAQ">BIOC</a>) shares dropped 9.6% to $4.4491 dipping over 25% on Monday. Biocept recently announced a 1-for-30 reverse stock split.</li>
<li>ToughBuilt Industries, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tblt#NASDAQ">TBLT</a>) fell 9.1% to $0.9277 after reporting results for its first quarter.</li>
<li>Peraso Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prso#NASDAQ">PRSO</a>) fell 8.3% to $0.3650 after gaining over 53% on Monday.</li>
<li>Zoom Video Communications, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zm#NASDAQ">ZM</a>) dropped 7% to $66.42. Zoom Video reported better-than-expected results for its first quarter and raised its full-year sales outlook.</li>
<li>BJ&#39;s Wholesale Club Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bj#NYSE">BJ</a>) dropped 6.4% to $65.18 following weak quarterly sales.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/05/32530348/dow-drops-over-100-points-lowes-earnings-top-views"> Dow Drops Over 100 Points; Lowe&#39;s Earnings Top Views</a>

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABCL

ACHV

ANGN

AUVI

BACK

BIOC

CVAC

CWBR

HTCR

IART

ICVX

KSPN

LEXX

LFCR

MBOT

MCLD

MHUA

MVLA

MVST

MYGN

NCPL

NEXI

NVGS

OCEA

ONCR

PACW

PRSO

QBTS

QTRX

RXRX

SHPH

SNMP

STRC

TBLT

TERN

TNON

TTOO

UFAB

VYGR

YELP

Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Cumberland Pharmaceuticals Announces FDA Clearance Cleared The Investigational New Drug Application For A Phase II Study In Patients With Idiopathic Pulmonary Fibrosis

<h3>Gainers</h3>
<ul>
<li>Applied UV, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/auvi#NASDAQ">AUVI</a>) shares rose 44.6% to $0.69 in pre-market trading after posting better-than-expected quarterly sales.</li>
<li>SeqLL Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sql#NASDAQ">SQL</a>) shares surged 34.3% to $0.5377 in pre-market trading after gaining over 19% on Monday. SeqLL recently posted a wider first-quarter loss.</li>
<li>HeartCore Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/htcr#NASDAQ">HTCR</a>) gained 21.1% to $1.55 in pre-market trading following better-than-expected first-quarter results.</li>
<li>Bone Biologics Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bblg#NASDAQ">BBLG</a>) shares gained 18.8% to $0.1960 in pre-market trading after gaining over 10% on Monday.</li>
<li>Movella Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mvla#NASDAQ">MVLA</a>) rose 18.5% to $2.28 in pre-market trading after jumping around 18% on Monday.</li>
<li>Cumberland Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cpix#NASDAQ">CPIX</a>) shares rose 14.4% to $1.99 in pre-market trading. The FDA recently approved expanded labeling for Cumberland Pharmaceuticals&rsquo; Caldolor, an intravenously delivered formulation of ibuprofen, to now include use in infants.</li>
<li>Navidea Biopharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/navb#NASDAQ">NAVB</a>) shares gained 14.1% to $0.1275 in pre-market trading after the company reported the sale of preferred shares totaling $1.1 million to new existing investors.</li>
<li>Yelp Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/yelp#NYSE">YELP</a>) gained 13.3% to $36.84 in pre-market trading. Activist investor TCS Capital Management is calling on Yelp to explore strategic alternatives including a sale, the Wall Street Journal reported.</li>
<li>Ohmyhome Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/omh#NASDAQ">OMH</a>) rose 12% to $5.82 in pre-market trading. The company recently announced it signed an MOU for the potential acquisition of a leading tech-enabled property management company in Singapore.</li>
<li>Orion Energy Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/oesx#NASDAQ">OESX</a>) shares climbed 10.3% to $1.60 in pre-market trading.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Kaspien Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kspn#NASDAQ">KSPN</a>) fell 41.1% to $0.36 in pre-market. Kaspien Holdings reported voluntary delisting from the Nasdaq Capital Market effective on or about June 12.</li>
<li>Biocept, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bioc#NASDAQ">BIOC</a>) shares dropped 23.6% to $3.77 in pre-market trading after dipping over 25% on Monday. Biocept recently announced a 1-for-30 reverse stock split..</li>
<li>Peraso Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prso#NASDAQ">PRSO</a>) fell 22.3% to $0.31 in pre-market trading after gaining over 53% on Monday.</li>
<li>Microvast Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mvst#NASDAQ">MVST</a>) fell 22.2% to $1.71 in pre-market trading after the U.S. Department of Energy reportedly canceled contract negotiations for another potential $200 million award for Microvast, per Reuters, citing a source familiar with the matter.</li>
<li>ToughBuilt Industries, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tblt#NASDAQ">TBLT</a>) fell 13.4% to $0.8820 in pre-market trading after reporting results for its first quarter.</li>
<li>Microbot Medical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mbot#NASDAQ">MBOT</a>) fell 13.1% to $2.77 in pre-market trading. Microbot Medical announced a $1.44 million registered direct offering of 655,569 shares of common stock at a price of $2.20 per share priced at the market under Nasdaq rules.</li>
<li>Hepion Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hepa#NASDAQ">HEPA</a>) fell 12.8% to $16.89 in pre-market trading. Hepion Pharmaceuticals shares jumped around 118% on Monday after the company announced results of its phase 2 study to treat liver function.</li>
<li>Netcapital Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ncpl#NASDAQ">NCPL</a>) shares dropped 10.6% to $2.15 in pre-market trading after gaining 22% on Monday.</li>
<li>D-Wave Quantum Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/qbts#NYSE">QBTS</a>) fell 7.7% to $0.9413 in pre-market trading after surging 110% on Monday.</li>
<li>Outlook Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otlk#NASDAQ">OTLK</a>) shares fell 6.8% to $1.52 in pre-market trading after jumping around 22% on Monday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/23/05/32523236/investor-optimism-improves-on-hopes-of-debt-ceiling-resolution"> Investor Optimism Improves On Hopes Of Debt Ceiling Resolution</a>

Pre-Market Outlook

BBLG

HEPA

NAVB

OESX

OTLK

Why Microvast Holdings Shares Are Trading Lower By Around 22%; Here Are 20 Stocks Moving Premarket

The FDA has approved expanded labeling for&nbsp;Cumberland Pharmaceuticals Inc&#39;s&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cpix#NASDAQ">CPIX</a>) Caldolor, an intravenously delivered formulation of ibuprofen,&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/23/05/n32392365/caldolor-now-fda-approved-for-treatment-of-fever-pain-in-infants" style="color:#4a6ee0; background:transparent; margin-top:0pt; margin-bottom:0pt" target="_blank">to now include use in infants</a>.&nbsp;
The non-narcotic agent may now be administered to treat pain and fever in patients three months to six months of age.&nbsp;
To support this expanded use of Caldolor, Cumberland sponsored a multi-center study in 21 hospitalized infants. All but one patient was treated with a single dose of the product.
The use of Caldolor for these indications is supported by evidence from one adequate and controlled open-label study in infants, along with additional safety data from four studies in 164 pediatric patients, supportive pediatric data from other approved ibuprofen products, and evidence from adequate and well-controlled studies in adults.
With this newly approved labeling, Caldolor is the only non-opioid product approved to treat pain in infants delivered through injection.&nbsp;
Cumberland previously announced FDA approval for use in pre-operative administration. The non-narcotic pain reliever may be administered just before surgery, enabling patients to wake up from their procedures in significantly less pain.&nbsp;
In addition, the company recently reported that it expects Caldolor to be eligible for special Medicare reimbursement under the Non-Opioids Prevent Addiction in the Nation Act (the NOPAIN Act), enacted as part of the Consolidated Appropriations Act of 2023.
Price Action:&nbsp;CPIX shares are up 8.59% at $1.79 on the last check Monday.

Health Care

Caldolor: The Only Non-Opioid Injectable Pain Reliever Approved for Use in Infants, Says FDA

Cumberland Pharmaceuticals Inc. Announces FDA Approval Of Caldolor

<h3>Gainers</h3>
<ul>
<li>Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) stock rose 30.3% to $2.15 during Monday's pre-market session. The market value of their outstanding shares is at $30.9 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) shares increased by 27.52% to $1.39. The market value of their outstanding shares is at $59.6 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) stock increased by 25.87% to $151.3. The company's market cap stands at $14.0 billion. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock moved upwards by 15.41% to $2.77. The market value of their outstanding shares is at $123.4 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) shares rose 14.12% to $1.6. The company's market cap stands at $18.5 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares increased by 13.49% to $0.2. The market value of their outstanding shares is at $5.9 million. As per the news, the Q1 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Athenex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNX#NASDAQ">ATNX</a>) stock declined by 53.5% to $0.53 during Monday's pre-market session. The market value of their outstanding shares is at $4.5 million. </li>
<li>Larimar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRMR#NASDAQ">LRMR</a>) stock declined by 20.95% to $4.0. The market value of their outstanding shares is at $173.0 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock declined by 20.07% to $0.78. The market value of their outstanding shares is at $1.5 million. The company's, Q1 earnings came out 2 days ago. </li>
<li>Dermata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) shares fell 11.88% to $2.3. The market value of their outstanding shares is at $1.9 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) stock decreased by 11.43% to $3.72. The market value of their outstanding shares is at $89.0 million. </li>
<li>Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) shares decreased by 9.81% to $23.0. The company's market cap stands at $564.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGS

ATNX

CVKD

DRMA

GNLX

Larimar Therapeutics, Inc. - Common Stock

LRMR

SRPT

TIVC

12 Health Care Stocks Moving In Monday's Pre-Market Session

Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) reported quarterly earnings of $0.11 per share. This is a 266.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported $9.22 million in sales this quarter. This is a 17.45 percent decrease over sales of $11.18 million the same period last year.

Cumberland Q1 Adj EPS $0.11 Up From $0.03 YoY, Sales $9.22M Down From $11.18M YoY

Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) reported quarterly losses of $(0.05) per share. This is a 61.54 percent increase over losses of $(0.13) per share from the same period last year. The company reported $9.12 million in sales this quarter. This is a 9.65 percent increase over sales of $8.32 million the same period last year.

Cumberland Q4 Adj. EPS $(0.05) Up From $(0.13) YoY, Sales $9.12M Up From $8.32M YoY

<h3>Companies Reporting Before The Bell</h3>
&bull; Cohen &amp; Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/COHN#AMEX">COHN</a>) is likely to report earnings for its fourth quarter.
&bull; Xtant Medical Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) is expected to report earnings for its fourth quarter.
&bull; Ferguson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) is likely to report quarterly earnings at $2.01 per share on revenue of $6.84 billion.
&bull; Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) is likely to report quarterly loss at $0.17 per share on revenue of $3.20 million.
&bull; Westwater Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WWR#AMEX">WWR</a>) is estimated to report earnings for its fourth quarter.
&bull; Voyager Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYGR#NASDAQ">VYGR</a>) is estimated to report quarterly loss at $0.55 per share on revenue of $4.19 million.
&bull; Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) is projected to report quarterly loss at $0.46 per share on revenue of $6.00 million.
&bull; Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) is likely to report earnings for its fourth quarter.
&bull; Dole (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOLE#NYSE">DOLE</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $2.26 billion.
&bull; OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) is likely to report quarterly loss at $0.17 per share on revenue of $20.69 million.
&bull; CorEnergy Infr Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CORR#NYSE">CORR</a>) is projected to report earnings for its fourth quarter.
&bull; AFC Gamma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFCG#NASDAQ">AFCG</a>) is expected to report quarterly earnings at $0.58 per share on revenue of $18.37 million.
&bull; Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $154.51 million.
&bull; Tremor Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMR#NASDAQ">TRMR</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $103.13 million.
&bull; Thor Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) is projected to report quarterly earnings at $1.13 per share on revenue of $2.49 billion.
&bull; Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) is likely to report earnings for its fourth quarter.
&bull; Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) is expected to report quarterly loss at $0.17 per share on revenue of $43.59 million.
&bull; Enfusion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENFN#NYSE">ENFN</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $40.00 million.
&bull; Ranger Energy Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNGR#NYSE">RNGR</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $171.20 million.
&bull; Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) is projected to report quarterly loss at $0.38 per share on revenue of $16.82 million.
&bull; Dick&#39;s Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) is likely to report quarterly earnings at $2.87 per share on revenue of $2.
&bull; 908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) is expected to report quarterly loss at $0.26 per share on revenue of $11.43 million.
&bull; Autolus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUTL#NASDAQ">AUTL</a>) is projected to report quarterly loss at $0.27 per share on revenue of $3.20 million.
&bull; Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) is projected to report quarterly loss at $0.07 per share on revenue of $101.66 million.
&bull; Landsea Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSEA#NASDAQ">LSEA</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $441.48 million.
&bull; Verona Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $3.57 million.
&bull; First Watch Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRG#NASDAQ">FWRG</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $187.25 million.
&bull; Squarespace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQSP#NYSE">SQSP</a>) is estimated to report quarterly earnings at $0.11 per share on revenue of $222.11 million.
&bull; Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) is estimated to report quarterly loss at $0.77 per share on revenue of $3.12 billion.
&bull; BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) is likely to report quarterly loss at $0.16 per share on revenue of $19.62 million.
&bull; Perfect (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PERF#NYSE">PERF</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $15.34 million.
&bull; Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) is expected to report earnings for its fourth quarter.
&bull; ESAB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESAB#NYSE">ESAB</a>) is expected to report quarterly earnings at $0.88 per share on revenue of $586.25 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) is estimated to report earnings for its fourth quarter.
&bull; Red Cat Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) is expected to report quarterly loss at $0.09 per share on revenue of $2.65 million.
&bull; Momentus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) is expected to report quarterly loss at $0.28 per share on revenue of $500 thousand.
&bull; Cherry Hill Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHMI#NYSE">CHMI</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $5.10 million.
&bull; Full House Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLL#NASDAQ">FLL</a>) is likely to report quarterly loss at $0.11 per share on revenue of $39.53 million.
&bull; CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) is projected to report earnings for its fourth quarter.
&bull; W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) is estimated to report quarterly earnings at $0.06 per share on revenue of $182.38 million.
&bull; Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is expected to report quarterly loss at $0.11 per share on revenue of $27.97 million.
&bull; Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) is expected to report quarterly loss at $0.55 per share on revenue of $3.48 million.
&bull; Intellicheck (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDN#NASDAQ">IDN</a>) is likely to report quarterly loss at $0.03 per share on revenue of $4.60 million.
&bull; Fuel Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEK#NASDAQ">FTEK</a>) is projected to report quarterly loss at $0.03 per share on revenue of $6.38 million.
&bull; Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $44.40 million.
&bull; Invesco National AMT-Free Municipal Bond ETFo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PZA#NYSE">PZA</a>) is estimated to report earnings for its fourth quarter.
&bull; VanEck Energy Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EINC#NYSE">EINC</a>) is projected to report earnings for its fourth quarter.
&bull; Maxeon Solar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>) is likely to report earnings for its fourth quarter.
&bull; TDCX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDCX#NYSE">TDCX</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $135.63 million.
&bull; Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) is likely to report quarterly loss at $0.23 per share on revenue of $10.42 million.
&bull; Couchbase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BASE#NASDAQ">BASE</a>) is expected to report quarterly loss at $0.34 per share on revenue of $38.26 million.
&bull; CarParts.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTS#NASDAQ">PRTS</a>) is expected to report quarterly loss at $0.11 per share on revenue of $151.18 million.
&bull; Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) is expected to report quarterly loss at $0.70 per share on revenue of $5.27 million.
&bull; Arlo Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARLO#NYSE">ARLO</a>) is expected to report quarterly loss at $0.10 per share on revenue of $107.44 million.
&bull; Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) is expected to report quarterly loss at $0.27 per share on revenue of $27.00 million.
&bull; Ero Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERO#NYSE">ERO</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $154.69 million.
&bull; Allied Motion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMOT#NASDAQ">AMOT</a>) is estimated to report quarterly earnings at $0.50 per share on revenue of $126.17 million.
&bull; Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) is likely to report quarterly earnings at $0.03 per share on revenue of $100.39 million.
&bull; Synchronoss Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCR#NASDAQ">SNCR</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $65.23 million.
&bull; Invesco DWA Industrials Momentum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRN#NASDAQ">PRN</a>) is projected to report quarterly loss at $0.50 per share on revenue of $3.97 million.
&bull; Profound Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>) is estimated to report quarterly loss at $0.36 per share on revenue of $2.72 million.
&bull; Agiliti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGTI#NYSE">AGTI</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $272.74 million.
&bull; Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) is projected to report quarterly earnings at $0.06 per share on revenue of $241.40 million.
&bull; CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is expected to report quarterly earnings at $0.43 per share on revenue of $624.95 million.
&bull; Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) is likely to report quarterly loss at $0.15 per share on revenue of $2.87 million.
&bull; Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRGY#NYSE">CRGY</a>) is estimated to report quarterly earnings at $0.74 per share on revenue of $617.40 million.
&bull; SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) is estimated to report quarterly loss at $0.17 per share on revenue of $8.74 million.
&bull; BSQUARE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSQR#NASDAQ">BSQR</a>) is projected to report earnings for its fourth quarter.
&bull; PCTEL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTI#NASDAQ">PCTI</a>) is expected to report quarterly earnings at $0.16 per share on revenue of $26.00 million.
&bull; Stitch Fix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) is likely to report quarterly loss at $0.32 per share on revenue of $393.57 million.
&bull; Harte-Hanks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HHS#NASDAQ">HHS</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $52.20 million.
&bull; Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) is estimated to report quarterly earnings at $3.12 per share on revenue of $214.33 million.
&bull; MasterBrand (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MBC#NYSE">MBC</a>) is projected to report quarterly earnings at $0.51 per share on revenue of $769.00 million.
&bull; Casey&#39;s General Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) is projected to report quarterly earnings at $1.60 per share on revenue of $3.59 billion.
&bull; Energy Vault Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) is projected to report quarterly loss at $0.15 per share on revenue of $65.45 million.
&bull; Akili (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKLI#NASDAQ">AKLI</a>) is likely to report quarterly loss at $0.30 per share on revenue of $80 thousand.
&bull; Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) is expected to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

Comments

Cumberland

Vendite allo scoperto

Cumberland (NASDAQ:CPIX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO